The pace of initial public offerings by Massachusetts biotechs continues to pick up steam, as a pair of Cambridge companies that previously filed to go public priced their shares this week.
Acceleron Pharma Inc., which is developing protein-based drugs to treat rare blood disorders, Friday said it will seek to raise about $65 million by offering 4.7 million shares to public investors at a price range of between $13 and $15 a share.
On Thursday, Bind Therapeutics Inc., which is developing programmable drugs to treat lung cancer and prostate cancer, indicated it plans to raise $71 million by selling 4.7 million shares at a range of $14 to $16.
Once they begin trading, Acceleron would be listed under the symbol XLRN, and Bind under the symbol BIND, on the Nasdaq stock exchange.
The two companies would join five other Bay State biotechs that have completed IPOs this year: Enanta Pharmaceuticals Inc. and Tetraphase Pharmaceuticals Inc. of Watertown and Cambridge-based Epizyme Inc., Bluebird Bio Inc., and Agio Pharmaceuticals Inc.
Another biotechnology company, Foundation Medicine Inc. of Cambridge, which is developing a diagnostic system to match cancer patients with effective treatments, registered for an IPO at the end of July, saying that it would also try to raise $86.2 million. It has yet to price its shares.